Treatment of Patients with Multiple Myeloma Over 65 Yr: More Tolerability or Better Response?

dc.contributor.authorTarkun, Pinar
dc.contributor.authorAtalay, Figen
dc.contributor.authorAtesoglu, Elif Birtas
dc.contributor.authorMehtap, Ozgur
dc.contributor.authorSimsek, Melih
dc.contributor.authorTerzi, Esra
dc.contributor.authorGeduk, Ayfer
dc.contributor.authorBalli, Fatih
dc.contributor.authorBatman, Adnan
dc.contributor.authorBaydemir, Canan
dc.contributor.authorHacihanefioglu, Abdullah
dc.contributor.orcID0000-0003-4384-2913en_US
dc.contributor.pubmedID25220635en_US
dc.contributor.researcherIDB-5507-2014en_US
dc.date.accessioned2024-02-21T07:52:51Z
dc.date.available2024-02-21T07:52:51Z
dc.date.issued2015
dc.description.abstractObjectiveTwo-thirds of newly diagnosed patients with multiple myeloma (MM) are over 65yr and/or physically unfit. Such patients are not eligible for high-dose chemotherapy or stem cell transplantation. The treatment aims in these patients should be to prolong survival by obtaining the best possible response, while maintaining good tolerability. The aim of our study was to evaluate the response to treatment and treatment-related toxicities in patients treated with conventional and novel protocols. MethodsThe records of 138 elderly (65yr) patients with MM were retrospectively evaluated. ResultsThe median overall survival(OS) of the patients was 46months. The median progression-free survival (PFS) was 18months. The OS and PFS of the patients treated with the conventional protocols did not differ significantly from those treated with the novel protocols. The statistical analysis of the quality of the response to the treatment with the conventional and novel therapies showed that complete remission (CR), combined with a very good partial response (VGPR), was significantly higher in the latter. However, the toxicities were higher in the novel treatment group. ConclusionThe novel drug protocols significantly increased the quality of the responses of elderly patients with MM to therapy, but they did not increase the patients' tolerability.en_US
dc.identifier.eissn1600-0609en_US
dc.identifier.endpage430en_US
dc.identifier.issn0902-4441en_US
dc.identifier.issue5en_US
dc.identifier.scopus2-s2.0-84926453533en_US
dc.identifier.startpage424en_US
dc.identifier.urihttp://hdl.handle.net/11727/11564
dc.identifier.volume94en_US
dc.identifier.wos000352633000008en_US
dc.language.isoengen_US
dc.relation.isversionof10.1111/ejh.12448en_US
dc.relation.journalEUROPEAN JOURNAL OF HAEMATOLOGYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergien_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectmultiple myelomaen_US
dc.subjectdrug toxicityen_US
dc.subjectelderlyen_US
dc.subjectquality of responseen_US
dc.titleTreatment of Patients with Multiple Myeloma Over 65 Yr: More Tolerability or Better Response?en_US
dc.typearticleen_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: